Display options
Cite
Mirabello L, Kratz CP, Savage SA, et al. Promoter methylation of candidate genes associated with familial testicular cancer. Int J Mol Epidemiol Genet. 2012;3(3):213-27
Mirabello, L., Kratz, C. P., Savage, S. A., & Greene, M. H. (2012). Promoter methylation of candidate genes associated with familial testicular cancer. International journal of molecular epidemiology and genetics, 3(3), 213-27.
Mirabello, Lisa, et al. "Promoter methylation of candidate genes associated with familial testicular cancer." International journal of molecular epidemiology and genetics vol. 3,3 (2012): 213-27.
Mirabello L, Kratz CP, Savage SA, Greene MH. Promoter methylation of candidate genes associated with familial testicular cancer. Int J Mol Epidemiol Genet. 2012;3(3):213-27. Epub 2012 Aug 31. PMID: 23050052; PMCID: PMC3459216.
Copy Download .nbib Format: NLM
Share it on

Int J Mol Epidemiol Genet. 2012;3(3):213-27. Epub 2012 Aug 31.

Promoter methylation of candidate genes associated with familial testicular cancer.

International journal of molecular epidemiology and genetics

Lisa Mirabello, Christian P Kratz, Sharon A Savage, Mark H Greene

Affiliations

  1. Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services Bethesda, Maryland, USA.

PMID: 23050052 PMCID: PMC3459216

Abstract

Recent genomic studies have identified risk SNPs in or near eight genes associated with testicular germ cell tumors (TGCT). Mouse models suggest a role for Dnd1 epigenetics in TGCT susceptibility, and we have recently reported that transgenerational inheritance of epigenetic events may be associated with familial TGCT risk. We now investigate whether aberrant promoter methylation of selected candidate genes is associated with familial TGCT risk. Pyrosequencing assays were designed to evaluate CpG methylation in the promoters of selected genes in peripheral blood DNA from 153 TGCT affecteds and 116 healthy male relatives from 101 multiple-case families. Wilcoxon rank-sum tests and logistic regression models were used to investigate associations between promoter methylation and TGCT. We also quantified gene product expression of these genes, using quantitative PCR. We observed increased PDE11A, SPRY4 and BAK1 promoter methylation, and decreased KITLG promoter methylation, in familial TGCT cases versus healthy male family controls. A significant upward risk trend was observed for PDE11A when comparing the middle and highest tertiles of methylation to the lowest [odds ratio (OR) =1.55, 95% confidence intervals (CI) 0.82-2.93, and 1.94, 95% CI 1.03-3.66], respectively; P(trend)=0.042). A significant inverse association was observed for KITLG when comparing the middle and lowest tertiles to the highest (OR=2.15, 95% CI 1.12-4.11, and 2.15, 95% CI 1.12-4.14, respectively; P(trend)=0.031). There was a weak inverse correlation between promoter methylation and KITLG expression. Our results suggest that familial TGCT susceptibility may be associated with promoter methylation of previously-identified TGCT risk-modifying genes. Larger studies are warranted.

Keywords: Promoter methylation; candidate gene; epidemiology; familial testicular cancer; testicular germ cell tumors

References

  1. Nat Genet. 2006 Jul;38(7):794-800 - PubMed
  2. Cancer Prev Res (Phila). 2011 Jan;4(1):6-8 - PubMed
  3. Nat Genet. 2006 Oct;38(10):1178-83 - PubMed
  4. Cell Cycle. 2003 Jul-Aug;2(4):281-2 - PubMed
  5. EXS. 1993;64:169-85 - PubMed
  6. Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3702-7 - PubMed
  7. Cancer Genomics Proteomics. 2007 Sep-Oct;4(5):359-67 - PubMed
  8. Int J Cancer. 2001 Apr 1;92(1):144-50 - PubMed
  9. Endocr Relat Cancer. 2010 Mar 08;17(2):R109-21 - PubMed
  10. J Med Genet. 2009 Dec;46(12):793-802 - PubMed
  11. Lancet. 1997 Dec 13;350(9093):1723-8 - PubMed
  12. Int J Impot Res. 2005 May-Jun;17(3):216-23 - PubMed
  13. BMC Med Genet. 2010 May 17;11:77 - PubMed
  14. Histol Histopathol. 2007 Dec;22(12):1413-24 - PubMed
  15. Int J Biochem Cell Biol. 2009 Jan;41(1):34-9 - PubMed
  16. Anal Biochem. 2004 Oct 1;333(1):119-27 - PubMed
  17. Anticancer Res. 2007 May-Jun;27(3B):1685-8 - PubMed
  18. Cancer Res. 2009 Jul 1;69(13):5301-6 - PubMed
  19. J Biol Chem. 2000 Oct 6;275(40):31469-79 - PubMed
  20. Nat Genet. 2004 May;36(5):497-501 - PubMed
  21. Nat Genet. 2010 Jul;42(7):604-7 - PubMed
  22. Sci STKE. 2007 Apr 24;2007(383):pe16 - PubMed
  23. Cancer Prev Res (Phila). 2011 Jan;4(1):23-33 - PubMed
  24. Genes Chromosomes Cancer. 2008 Mar;47(3):247-52 - PubMed
  25. Br J Cancer. 2004 May 4;90(9):1765-70 - PubMed
  26. Hum Mol Genet. 2007 Sep 15;16(18):2233-40 - PubMed
  27. Mol Endocrinol. 2000 May;14(5):682-99 - PubMed
  28. J Natl Cancer Inst. 2005 Jul 20;97(14):1056-66 - PubMed
  29. Nat Genet. 2009 Jul;41(7):811-5 - PubMed
  30. Am J Hum Genet. 2005 Dec;77(6):1034-43 - PubMed
  31. Nat Genet. 2009 Jul;41(7):807-10 - PubMed
  32. Hum Mol Genet. 2006 Feb 1;15(3):443-51 - PubMed
  33. J Med Genet. 2011 Jul;48(7):473-6 - PubMed
  34. Br J Cancer. 2008 Nov 18;99(10):1748-53 - PubMed
  35. Nat Genet. 2009 Jan;41(1):112-7 - PubMed
  36. Cancer Res. 2008 Jul 1;68(13):5193-7 - PubMed

Publication Types

Grant support